Slide 1: ASX Announcement: Mayne Pharma 3Q Investor Presentation
ASX Announcement MAYNE PHARMA 3Q INVESTOR PRESENTATION 7 May 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), today provides an investor presentation providing an overview of its 3Q results, which were announced to the market on 29 April 2026. A copy of
Slide 2: Mayne Pharma Group Limited Investor Presentation 3Q FY26
For personal use only Mayne Pharma Group Limited Investor Presentation 3Q FY26 Aaron Gray CEO 7 May 2026
Slide 3: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market For personal use only disclosures. This material is not intended to be relied upon as advice to invest
Slide 4: Snapshot
Snapshot Corporate Summary1,2 • Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more For personal use only accessible medicines in Dermatology and Women’s Health Share price (ASX:MYX) $2.67 Shares on
Slide 5: Mayne Pharma in 2026
Mayne Pharma in 2026 Branded Product Sales Now Represent a Significant Proportion (%) of Mayne Pharma’s Net Sales, Driving Margin Expansion For personal use only FY24 FY25 1H FY26 32% 68% 21% 79% 16% 84% 68% Branded │ 32% Generic 79% Branded │ 21% Generic 84% Branded │ 16% Generic 56% Gross Margin 6
Slide 6: Global Sales & Headcount
Global Sales & Headcount Global footprint UNITED STATES For personal use only $339 million AUSTRALIA & NEW ZEALAND $42 million T O TA L H E A D C O U N T T O TA L F Y 2 5 S A L E S CANADA 467 $408.1 million $20 million EUROPE Employees1 $4 million ASIA $3 million 5 1. As at 31 December 2025
Slide 7: Q3 FY26 Review
For personal use only Q3 FY26 Review
Slide 8: 3Q FY26 Financial Results
3Q FY26 Financial Results1 3Q FY26 delivered resilient earnings, with margin discipline underpinning performance For personal use only $85.2m 63% -$1.4m Revenue Gross margin Underlying EBITDA2 up 1% from 3Q FY25 up from 59% 3Q FY25 up 57% from 3Q FY25 $17.9m $28.3m $86.7m Total direct segment Adjust
Slide 9: 3Q FY26 Unaudited EBITDA & Cash Flow
3Q FY26 Unaudited EBITDA & Cash Flow1 EBITDA ($m) For personal use only Restructuring & Other -1.4 • Reported EBITDA of -$4.5 million: an improvement of 10% 1.0 on the pcp Legal costs Underlying EBITDA -4.5 2.1 • Underlying EBITDA of -$1.4 million: improvement of 57% on the pcp • 3Q of each FY perio
Slide 10: 3Q FY26 Operating & Financial Highlights (Segments)
3Q FY26 Operating & Financial Highlights (Segments) For personal use only Women’s Health Dermatology • Women’s Health growth strategy is focused on increasing share of • TWYNEO® achieved better-than-expected commercial formulary voice, improving field force effectiveness and converting demand covera
Slide 11: 3Q FY26 Operating & Financial Highlights (Segments)
3Q FY26 Operating & Financial Highlights (Segments) International Corporate For personal use only • Strong sales growth associated with NEXTSTELLIS® following PBS • Do not expect material earnings impact from US tariff proclamation approval in late September 2025: focus on patient and prescriber on
Slide 12: Mayne Pharma Disintermediation & DistributeRx
For personal use only Mayne Pharma Disintermediation & DistributeRx
Slide 13: Mayne Pharma Disintermediation
Mayne Pharma Disintermediation Timeline Disintermediation: Involves removing the intermediaries (wholesalers or others) between the manufacturer For personal use only (Mayne Pharma) and the patient DistributeRx is Mayne Pharma's direct-to-patient distribution platform with Adelaide Apothecary servin
Slide 14: Disintermediation – What are the benefits?
Disintermediation – What are the benefits? For personal use only Manufacturer Benefits Patient Benefits For example: Inventory – tighter controls and lower returns Transparent and predictable costs Greater certainty on co-pay arrangements Stronger negotiating position with spec pharmacy v wholesale
Slide 15: DistributeRx: Prescription Access Made Simple
PRESCRIPTION ACCESS MADE SIMPLE For personal use only DistributeRx partners with manufacturers, providers, and pharmacies to improve patient access and offer predictable prices • Currently, 31 Mayne Pharma + 178 non-Mayne Pharma dermatology products offered • All Mayne Pharma Dermatology sales reps
Slide 16: DistributeRx Launch Metrics for Initial Month of March 2026
DistributeRx Launch Metrics for Initial Month of March 2026 For personal use only +72% +92% +73% Versus internal prescription Rx growth versus the pcp Rx growth versus pre-launch (Rx) forecast (March 2025) prescription volumes (Feb) ~6,400 ~1,600 ~70% New prescribers added since Of targeted salesfor
Slide 17: FY26 outlook
FY26 outlook For personal use only Mayne Pharma's strategic priorities are focused on driving sustainable growth across its Women's Health and Dermatology segments through dedicated commercial investment, refreshed marketing, and the continued build-out of the DistributeRx ecosystem, while actively
Slide 18: For further information contact
For personal use only For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit https://www.maynepharma.com/investo
Slide 19: Appendix
For personal use only Appendix
Slide 20: FY25 Snapshot - Segments
FY25 Snapshot - Segments For personal use only FY25 Revenue Contribution FY25 Segment Contribution FY25 Total Direct Contribution ($m, % of total) ($m, % of total) $7.4, 7% $75.6, 18% $178.4, 44% $40.2, 37% $109.7m $154.1, 38% $62.0, 56% 76% on pcp Women’s Health Dermatology International 19
Slide 21: The US Pharmacy Distribution and Reimbursement System
The US Pharmacy Distribution and Reimbursement System for Patient- Administered, Outpatient Brand-Name Drugs Services agreement Formulary agreement Wholesaler payment Services contract For personal use only for product GPO Third-party payer/ The Problem Manufacturer Rebates (DIR) Health Plan & Fees
Slide 22: Mayne Pharma Model to Support Efficiency & Profitability
Mayne Pharma Model to Support Efficiency & Profitability For personal use only The Solution Manufacturers The Mayne Pharma approach is simple, efficient, and direct: • Simple — Fewer intermediaries mean clearer pricing for clinicians and more consistent access to therapy for patients. Pharmacy • Eff
Slide 23: Earn-Out and Deferred Consideration Liabilities - Update
Earn-Out and Deferred Consideration Liabilities - Update Royalties Milestones For personal use only TXMD: US$100m in net revenue (US$5m milestone payment) 8% Net Sales on all TXMD Licensed Products TXMD: US$200m in net revenue (US$10m milestone payment) (ANNOVERA®, IMVEXXY®, BIJUVA®) TXMD: US$300m i
Slide 24: Orange Book Listed Patents – Major Branded
Orange Book Listed Patents – Major Branded Last Patent Expiry Women’s Health Last Patent Expiry Dermatology For personal use only 2030 2032 2034 2034* 2035** 2039 2039 2041 2043 2041 Source: Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. * Paragraph IV challenges for I